|
1
|
10
|
8ds7M |
Tumor-activated antibody derivatives targeting ctla4 |
|
42
|
216
|
8ds7H |
Tumor-activated antibody derivatives targeting ctla4 |
|
56
|
219
|
8ds7L |
Tumor-activated antibody derivatives targeting ctla4 |
|
31
|
122
|
8iiuA |
Anti-vegf nanobody |
|
660
|
2719
|
7mp6A |
Neurofibromin homodimer |
|
614
|
2016
|
7mp5A |
Autoinhibited neurofibrobmin |
|
453
|
2016
|
7mocA |
Neurofibromin core |
|
39
|
114
|
7dpnA |
Crystal structure of brd2(bd1)with ligand zb-bd-224 bound |
|
52
|
237
|
7e5nA |
Crystal structure of cis assembled trop-2 |
|
139
|
523
|
7vxgA |
Non-receptor protein tyrosine phosphatase shp2 in complex with allosteric inhibitor tk-453 |
|
47
|
211
|
7segB |
Crystal structure of the complex of cd16a bound by an anti-cd16a fab |
|
36
|
171
|
7segC |
Crystal structure of the complex of cd16a bound by an anti-cd16a fab |
|
38
|
112
|
7dpoA |
Crystal structure of brd2(bd2)with ligand zb-bd-224 bound |
|
37
|
220
|
7segA |
Crystal structure of the complex of cd16a bound by an anti-cd16a fab |
|
33
|
223
|
7f9wB |
Cd25 in complex with fab |
|
9
|
161
|
7f9wA |
Cd25 in complex with fab |
|
34
|
218
|
7f9wC |
Cd25 in complex with fab |
|
45
|
194
|
7eaxA |
Crystal complex of p53-v272m and antimony ion |
|
44
|
108
|
7f5dA |
Crystal structure of bptf-brd with ligand dc-bpi-03 bound |
|
79
|
276
|
8ek5A |
Engineered scfv 10lh bound to phox2b/hla-a24:02 |
|
0
|
9
|
8ek5C |
Engineered scfv 10lh bound to phox2b/hla-a24:02 |
|
63
|
247
|
8ek5E |
Engineered scfv 10lh bound to phox2b/hla-a24:02 |
|
14
|
99
|
8ek5B |
Engineered scfv 10lh bound to phox2b/hla-a24:02 |
|
52
|
109
|
8x2qA |
The crystal structure of apc from biortus. |
|
85
|
300
|
8wjyA |
Pkmyt1_cocrystal_cpd 4 |
|
43
|
108
|
7f5eA |
Crystal structure of bptf-brd with ligand dc-bpi-11 bound |
|
39
|
108
|
7f5cA |
Crystal structure of bptf-brd with ligand dc-bpi-07 bound |
|
77
|
331
|
8ariA |
Cryo-em structure of human ctbp1/rai2(303-362) delta(331-341) filament |
|
1
|
22
|
8aria |
Cryo-em structure of human ctbp1/rai2(303-362) delta(331-341) filament |
|
80
|
249
|
8byuA |
Crystal structure of hexabody-cd38 fab in complex with cd38 |
|
40
|
133
|
7yl2A |
Crystal structure of the first bromodomain of human brd4 in complex with the inhibitor y07004 |
|
48
|
213
|
8byuL |
Crystal structure of hexabody-cd38 fab in complex with cd38 |
|
47
|
222
|
8byuH |
Crystal structure of hexabody-cd38 fab in complex with cd38 |
|
203
|
901
|
8haeA |
Cryo-em structure of hace1 dimer |
|
198
|
906
|
8h8xA |
Cryo-em structure of hace1 monomer |
|
41
|
212
|
8cyhL |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
53
|
241
|
8cz8B |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
58
|
288
|
8cxcM |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
32
|
217
|
8cxcH |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
13
|
107
|
8cxcA |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
45
|
148
|
8cz8E |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
72
|
295
|
8cyhM |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
38
|
220
|
8cyhH |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
55
|
245
|
8cz8A |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
36
|
212
|
8cxcL |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
21
|
117
|
8cxcB |
Novel anti-mesothelin antibodies enable crystallography of the intact mesothelin ectodo- main and engineering of potent, t cell-engaging bispecific therapeutics |
|
92
|
264
|
7yc9A |
Co-crystal structure of btk kinase domain with inhibitor |
|
31
|
123
|
7ygiC |
Crystal structure of p53 dbd domain in complex with azurin |
|
45
|
198
|
7ygiA |
Crystal structure of p53 dbd domain in complex with azurin |
|
24
|
116
|
7wn8A |
Crystal structure of antibody (bc31m5) binds to cd47 |
